Alloantigen-stimulated induction and release of CD30 in patients with end-stage renal failure

• Verfasst von: Velásquez, Sonia Y. [VerfasserIn]
• Verfasst von: Süsal, Caner [VerfasserIn]
• Verfasst von: Opelz, Gerhard [VerfasserIn]
• Titel: Alloantigen-stimulated induction and release of CD30 in patients with end-stage renal failure
• Verf.angabe: Sonia Y. Velásquez, Caner Süsal, Gerhard Opelz, Luis F. García, Cristiam M. Alvarez
• Umfang: 7 S.
• Fussnoten: Gesehen am 17.10.2018
• Titel Quelle: Enthalten in: Human immunology
• Jahr Quelle: 2012
• Band/Heft Quelle: 73(2012), 11, S. 1102-1108
• ISSN Quelle: 1879-1166
• DOI: doi:10.1016/j.humimm.2012.08.015
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1582027994

Abstract

High serum levels of soluble CD30 (sCD30) are associated with poor renal allograft survival, and regulatory T cells (Tregs) influence allograft survival depending on CD30 signaling. However, how sCD30 modulates alloimmune responses remains poorly understood. We measured the level of Tregs and sCD30 in patients with end-stage renal failure (ESRF) and analyzed whether allo- or polyclonal stimulation of the patients’ T cells results in the expression and release of CD30. ESRF patients showed increased serum sCD30 levels and lower percentages of circulating Tregs as compared to healthy controls (HC) (p<0.001 and 0.024). Polyclonal and allogeneic stimulation resulted in higher expression of CD30, and after polyclonal stimulation, ESRF patients showed higher percentages of CD30-expressing T cells than HC (p<0.001). Compared to autologous stimulation, allogeneic stimulation induced significantly higher expression of CD30 on T cells of ESRF patients only. After polyclonal as well as allogeneic stimulation, an increased sCD30 content was found in culture supernatants of both ESRF patients and HC (p<0.001). Together with decreased Tregs, high serum sCD30 and increased induction of CD30 on T cells after polyclonal stimulation may explain exacerbated alloimmune responses and poor allograft survival in ESRF patients in whom immunosuppression is not able to control the alloimmune response.